Clinical Competition Candidate
VERKAZIA
VERKAZIA carries product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 35 months away. Active clinical competition may compress the generic entry window.
LOE window
35months
to latest listed patent expiry (June 2, 2029)
Expiry attractiveness: 5/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 7
Complexity score: 3/5
Clinical competition
Score: 5/5
Active trials linked: 300
Phase 2/3 trials: 160
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: CYCLOSPORINE
Applicant (NDA holder): HARROW EYE LLC
Confidence: High